Pune, India, December , 2017/MRFR Press Release/- Market Research Future published a Half Cooked research report on “Global Autism Disorder and Treatment Market Research Report – Forecast to 2022 ” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022 .
The Global Autism Disorder and Treatment Market is currently dominated by various few players. Bristol-Myers Squibb and Otsuka Holdings Co., Ltd. are one of those by holding a strong share in the market. Bristol-Myers Squibb is a U.S. based pharmaceutical company and Otsuka Holdings Co., Ltd. has head office in Japan. Both the companies in collaboration introduced ABILIFY® (aripiprazole) drug for the treatment of conditions associated with autistic disorder.
The drug had received approval November 20, 2009. Currently, there are only two FDA approved drugs for autistic disorder in the market i.e., Abilify (aripiprazole) and risperidone. Risperidone is a second-generation antipsychotic drug, received approval from FDA to treat autistic disorders in 2006. Risperidone was introduced by Janssen Pharmaceuticals, Inc. Janssen Pharmaceuticals operates as a subsidiary of Johnson & Johnson Services, Inc. by manufacturing prescription pharmaceutical products. Risperidone, despite of its benefits, has its known side effects that clinicians have to balance for a subset of autistic people.
Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/1605 .
Autism spectrum disorder (ASD) is a group of complex neurological disorders characterized by varied patterns of behaviour, and problems with social communication and interaction. The major signs, and symptoms of ASD includes compulsive behaviour, inappropriate social interaction, learning disability, anxiety, sensitivity to sound, repetitive movements, and many others. As per the 2017 reviewed data suggested by Centers for disease control and prevention, it is observed that nearly 1 in 68 children has been diagnosed with autism spectrum disorder (ASD). It is also reported that the condition is 4.5 times more common among boys than among girls.
On considering the economic costs, it is observed that around USD 11.5 billion – 60.9 billion have been invested per year for patients dealing with ASD n the United States. In addition to medical costs, other behavioral interventions for children with ASD costs around USD 40,000 – 60,000 per child per year.
Notably, rising awareness about the condition is the key factor driving the autism disorder and treatment market. From the current scenario it is found that various government or privately held societies are continuously putting efforts to make people aware of autism disorder. For instance, on June 1, 2017, the U.S. based Autism Society conducted 49th annual conference focuses on quality of life. Rising research & development activities have also attracted a great deal of attention. The Autism CARES Act extended federal coverage of autism research activities by five years with $1.3 billion funding. Despite these significant driving factors, there are some issues associated with market. Patent expiration of drugs is expected to decline the market growth in near future.
Order a Premium 90 Pages Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=1605 .
The Autism Disorder and Treatment Market is expected to be concentrated across the eight major countries such as US, Canada, France, UK, Germany, Spain, Italy, and, Japan. Regional market analysis reflects the dominance of developed world on the Autism disorder treatment market. North America leads the world and is closely followed by Europe. The Asian continent is led by Japan. A close observation will reflect the fact that increasing screening is the likely cause of increasing Autism cases. This reflects an untapped and unmet needs of the developing world. Thus the market will be dominated by developed regions in the years to come and only after advent of a specific drug will the developing region market pick up. Market for non-pharmacological treatment especially in the developing world will be more affected by government policies and rising incomes.
Products in the Pipeline:
Due to the rising demand, and to meet the untapped and unmet needs various companies are coming up with innovative autism treatment products. For instance, RG7314, by F. Hoffmann-La Roche Ltd, is a potent small molecule antagonist of the V1A vasopressin receptor is under clinical trials to treat Autism spectrum disorders. Various other companies such as, APeT Holding BV, BioCrea GmbH, Coronis Partners Ltd., Curemark LLC, Heptares Therapeutics Limited, Intra-Cellular Therapies Inc., Saniona AB, and others are continuously putting efforts to introduce new effective drugs to treat autism , and related problems. Global key Players : GlaxoSmithKline plc (U.K), pfizer inc. (U.S.), Eli Lilly and Company (U.S.). Allergan (Ireland), Merck & CO Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Consern Pharma Private Limited (India) are some of the prominent players profiled in MRFR Analysis and are at the forefront of competition in the Global Autism Disorder and Treatment Market.
Major Table of Content for Autism Disorder and Treatment Market:
1 Report Prologue
2 Market Introductions
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
3 Research Methodologies
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
Ask to Expertise @ https://www.marketresearchfuture.com/enquiry/1605 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312